Tinnitus Research Digest: Two Trials Recruiting, Animal Study, and a Debate Over Definition

This is an ongoing randomised controlled trial (RCT) registered on ClinicalTrials.gov. Based on the available information, full study details including sample size targets, intervention protocols, and outcome measures have not yet been published — the trial is actively recruiting as of September 2025.

The study is described as Canada’s first large guided internet-based cognitive behavioural therapy (iCBT) trial for tinnitus. Guided iCBT means participants work through a structured digital programme with support from a therapist, rather than attending in-person sessions. The trial is designed to evaluate whether this format can deliver clinically meaningful reductions in tinnitus distress within a public healthcare context.

No results are available yet. Because this is a registered trial rather than a published study, there are no findings to report at this stage.

Key remaining questions include: What is the target sample size, and will it be adequately powered to detect a meaningful effect? How does the guided component compare to unguided digital programmes? And will the trial measure cost-effectiveness alongside clinical outcomes — a factor that matters for public funding decisions in systems like Canada’s provincial health plans?

This is a registered randomised controlled trial comparing two active treatments for chronic subjective tinnitus. Based on the available information from the ClinicalTrials.gov record, full protocol details and results have not been published — the trial was registered in November 2023 and may still be ongoing or awaiting publication.

The study tests whether transcutaneous vagus nerve stimulation (tVNS) — a non-surgical form of nerve stimulation applied through the skin — paired with tailor-made notched music training produces greater reductions in tinnitus severity than notched music training alone. Notched music therapy involves listening to music with the frequency band around a patient’s tinnitus pitch removed, with the aim of reducing auditory cortex activity at that frequency.

No results are available from this specific trial at this stage. The design addresses a clinically relevant question: both approaches have shown some effect in earlier smaller studies, but whether combining them produces added benefit over either alone has not been established in a well-powered trial.

Remaining questions include: What is the trial’s sample size, and has recruitment been completed? What outcome measures are being used — tinnitus handicap inventory, visual analogue scales, or audiological measures? And how long is the follow-up period? Replication in independent centres would be needed before any combined protocol could be considered standard care.

This preclinical study, authored by Zhang and colleagues, investigated whether photobiomodulation — a technique using specific wavelengths of light to modulate cellular activity — could reverse the auditory cortex overactivity seen in noise-induced tinnitus. The research was conducted in animal models; no human participants were involved.

Based on the available information from the title and author metadata, the study examined GluN1-mediated mechanisms — GluN1 is a subunit of the NMDA receptor, which plays a role in synaptic plasticity. The researchers report that photobiomodulation was associated with reversal of auditory cortical hyperexcitability and a restoration of synaptic plasticity balance in the animals studied.

Because no abstract was available, the specific model used (species, noise exposure protocol, sample sizes per group) cannot be reported here. This is a meaningful limitation in assessing the study’s strength.

As with all animal research, the central remaining question is whether these effects translate to humans. The pathway from a positive animal study to a clinical treatment typically involves years of safety and dose-finding work, followed by phased human trials. The NMDA receptor pathway has been studied in other neurological conditions, but whether photobiomodulation can reach and modulate auditory cortex tissue in humans has not been established. Independent replication in animal models would be a necessary first step before any human work could begin.

This is a 2021 narrative review by Salvi and colleagues examining the neural mechanisms by which certain drugs cause tinnitus and hyperacusis through ototoxicity — damage to the inner ear or auditory nervous system caused by medication. The review covers how specific drug classes affect cochlear and central auditory processing, contributing to phantom sound perception.

Based on the available information from the title and authorship metadata, no abstract was accessible for this record. The specific drugs reviewed, the evidence quality assessed, and the neural pathways discussed cannot be fully summarised here.

The review is now four years old. It addresses a clinically relevant topic — some patients develop tinnitus as a side effect of medications including certain antibiotics, chemotherapy agents, and anti-inflammatory drugs — but it does not present new treatment options for drug-induced tinnitus. Reviews of neural mechanisms are primarily useful for researchers and clinicians seeking to understand causation rather than for patients seeking actionable guidance.

Remaining questions for this area include: whether any of the identified mechanisms represent druggable targets for prevention or reversal, and whether more recent research has advanced understanding of individual susceptibility to ototoxic tinnitus. Given the 2021 publication date, more current literature may have extended or revised some of these findings.

This theoretical paper by Hashir Aazh, published in Frontiers in Audiology and Otology in early 2026, takes a philosophical approach to a deceptively basic question: can tinnitus be precisely defined? The paper does not present clinical trial data or experimental findings. It is a conceptual analysis.

Aazh uses a Socratic method to examine candidate features of tinnitus — such as occurring in wakefulness, persisting beyond fleeting moments, having a sound-like character, and lacking semantic content — and tests whether each feature truly distinguishes tinnitus from related phenomena like auditory hallucinations, musical earworms, or dream sounds. The paper argues that existing definitions struggle to draw these boundaries clearly and that several core questions remain empirically unresolved.

The paper’s key contribution is separating tinnitus as a perceptual experience from the distress it causes and the meaning patients attribute to it — a distinction with implications for how outcome measures in clinical trials are designed.

Limitations are inherent to the method: this is philosophical analysis, not empirical research. It generates questions rather than answers. The value lies in whether the research community takes these conceptual refinements seriously when designing future studies and measurement tools. Whether the proposed framework gains traction will depend on uptake in clinical and research settings.